U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. RemedyRepack Inc. - 03/31/2015
  1. Warning Letters


RemedyRepack Inc.

RemedyRepack Inc.

United States

Issuing Office:
Center for Drug Evaluation and Research

United States


Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 Silver Spring, MD  20993 


CERTIFIED MAIL                                                                                                            
March 31, 2015
Tom Bartlebaugh
RemedyRepack Inc.
655 Kolter Dr
Indiana, PA 15701-3570 USA
Dear Tom Bartlebaugh:
The United States Food and Drug Administration (FDA) has reviewed your firm’s listing information provided for Colchicine Tablet (NDC 49349-061). Our review revealed the listing for this product is inaccurate. Prompt action must be taken to correct this deficiency.
Section 510 (j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) outlines the requirements for registration and listing of drug products. In the case of Colchicine Tablet (NDC 49349-061), the listing must include a reference to the authority for marketing such a drug.[1]  
A review of the listing for Colchicine Tablet (NDC 49349-061) reveals that the product’s listing does not list the correct application number. The submitted listing information includes a number that does not refer to the listed product. Your firm is not the holder of record for specified application number and the application number does not refer to the listed drug. 
Your firm failed to fulfill its listing obligations under Section 510(j) of the FD&C Act, which is a prohibited act under Section 301(p) [21 U.S.C. 360(j) and 331(p)]. In addition, your firm’s failure to fulfill its listing obligations misbrands the product under Section 502(o) of the FD&C Act. Introduction or delivery for introduction into interstate commerce of a misbranded product is a prohibited act under Section 301(a) [21 U.S.C. 352(o) and 331(a)].
This information must be corrected to ensure its accuracy. Information from your firm’s registration and product listing are accessible not only to FDA, but to other interested parties, including consumers. If this product appears on the online NDC Directory, it will be removed from public viewing on the same date this letter is issued to you, until the required corrections are made. This is an effort to maintain a correct and accurate database in order to protect and promote the public health.
Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct this violation. Your response should include an explanation of each step being taken to prevent the recurrence of violations and copies of supporting documentation. If you cannot complete these corrective actions within fifteen working days, state the reason for the delay and the date by which you will have completed the correction.
Your reply should be sent to:
Leyla Rahjou-Esfandiary, Pharm. D.
Pharmacist, Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration
Mail Stop HFD-300
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
If you have any questions about the content of this letter, please contact edrls@fda.hhs.gov. Include the case identification number of Case_ID_422456 on all correspondence.
Finally, you should know that this letter is not intended to be an all-inclusive list of the violations found in your firm’s registration and product listing. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the product into compliance.
Ilisa B.G. Bernstein, Pharm.D., J.D.
Deputy Director, Office of Compliance
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Cc: Philadelphia District Office

[1] See FD&C Act Section 510 (j)(1)(A).

Close Out Letter

Back to Top